Wedmont Private Capital Decreases Stake in Jazz Pharmaceuticals PLC $JAZZ

Wedmont Private Capital cut its stake in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 66.2% during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 2,001 shares of the specialty pharmaceutical company’s stock after selling 3,911 shares during the period. Wedmont Private Capital’s holdings in Jazz Pharmaceuticals were worth $223,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Nuveen LLC acquired a new position in shares of Jazz Pharmaceuticals in the 1st quarter valued at approximately $62,362,000. Fuller & Thaler Asset Management Inc. raised its position in shares of Jazz Pharmaceuticals by 41.7% in the 1st quarter. Fuller & Thaler Asset Management Inc. now owns 1,331,011 shares of the specialty pharmaceutical company’s stock valued at $165,245,000 after purchasing an additional 391,660 shares in the last quarter. Perpetual Ltd raised its position in shares of Jazz Pharmaceuticals by 60.2% in the 1st quarter. Perpetual Ltd now owns 952,172 shares of the specialty pharmaceutical company’s stock valued at $118,212,000 after purchasing an additional 357,784 shares in the last quarter. Dimensional Fund Advisors LP raised its position in shares of Jazz Pharmaceuticals by 14.4% in the 1st quarter. Dimensional Fund Advisors LP now owns 2,328,430 shares of the specialty pharmaceutical company’s stock valued at $289,066,000 after purchasing an additional 293,360 shares in the last quarter. Finally, Goldman Sachs Group Inc. raised its position in shares of Jazz Pharmaceuticals by 147.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 351,609 shares of the specialty pharmaceutical company’s stock valued at $43,652,000 after purchasing an additional 209,667 shares in the last quarter. 89.14% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages have issued reports on JAZZ. Zacks Research raised Jazz Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Friday, August 15th. Royal Bank Of Canada upped their price target on Jazz Pharmaceuticals from $145.00 to $151.00 and gave the company an “outperform” rating in a research report on Thursday, August 28th. Morgan Stanley upped their price target on Jazz Pharmaceuticals from $162.00 to $163.00 and gave the company an “overweight” rating in a research report on Thursday, August 28th. The Goldman Sachs Group upped their price target on Jazz Pharmaceuticals from $162.00 to $185.00 and gave the company a “buy” rating in a research report on Friday, August 29th. Finally, Needham & Company LLC reissued a “buy” rating and set a $202.00 price target on shares of Jazz Pharmaceuticals in a research report on Thursday, August 28th. Fourteen equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $178.67.

Jazz Pharmaceuticals Trading Up 1.5%

Shares of JAZZ stock opened at $130.18 on Tuesday. The stock has a 50-day simple moving average of $120.76 and a 200 day simple moving average of $115.88. Jazz Pharmaceuticals PLC has a fifty-two week low of $95.49 and a fifty-two week high of $148.06. The stock has a market capitalization of $7.90 billion, a P/E ratio of -19.34, a P/E/G ratio of 7.96 and a beta of 0.24. The company has a quick ratio of 1.37, a current ratio of 1.62 and a debt-to-equity ratio of 1.17.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) earnings per share for the quarter, missing the consensus estimate of ($5.61) by ($2.64). Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. The firm had revenue of $1.05 billion for the quarter, compared to the consensus estimate of $1.05 billion. During the same period in the prior year, the business earned $5.30 EPS. The company’s quarterly revenue was up 2.1% compared to the same quarter last year. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. On average, sell-side analysts expect that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current fiscal year.

Insider Transactions at Jazz Pharmaceuticals

In related news, Director Bruce C. Cozadd sold 6,000 shares of the stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $128.62, for a total value of $771,720.00. Following the completion of the sale, the director directly owned 429,973 shares of the company’s stock, valued at approximately $55,303,127.26. This represents a 1.38% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 4.30% of the company’s stock.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.